Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSCs in Acute Lung Injury
NCT04951882Phase 1Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jun 2021
- Primary completion
- Dec 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised trial of human umbilical cord derived mesenchymal stem cells in acute lung injury (ALI) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Ratio of Partial Pressure of Arterial Oxygen to Fraction of Inspired Oxygen at Day 28. Status: unknown.
02
Drugs
human umbilical cord derived mesenchymal stem cells
03
Conditions
acute lung injury (ALI)
Beyond the preview
Go deeper on NCT04951882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04951882.